Neuromodulation of Motivation and Reward Oscillations (NEMO)
Delta and Theta-Frequency Transcranial Alternating Stimulation Neuromodulation of Motivation and Reward Oscillations in Disorder of Reward Dysfunction.
Cannabis use disorder (CUD) and major depressive disorder (MDD) are among the most prevalent psychiatric conditions in the United States, affecting an estimated 20.6 million and 21 million adults respectively. Both disorders are characterized by anhedonia, diminished motivation, and blunted neural reward sensitivity. This shared dysregulated reward-processing may reflect a common prefrontal oscillatory dysfunction, centralized in mesolimbic dopaminergic reward pathways. This proposed project aims to investigate if transcranial alternating current (tACS) can modulate motivational behaviours and neural reward responsivity in participants with MDD and/or CUD during an effortful reward task. The investigators hypothesize that delta transcranial alternating current stimulation will produce a greater neural reward responsivity (RewP), and motivational behaviour during an effortful reward task.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Disrupted reward processing is a transdiagnostic feature that plays a central role in the development, and maintenance of anhedonia in Cannabis Use Disorder (CUD) and Major Depressive Disorder (MDD). Reward positivity (RewP) is an event-related potential (ERP) component derived from electroencephalogram (EEG) data, associated with motivation, reward responsivity and valuation. This neural signature originates in the medial and dorsolateral prefrontal cortexes. In MDD, reduced RewP has been associated with decreased willingness to expend effort for reward. Research of CUD and RewP is scarce, but dampened RewP has been demonstrated across different substances use disorders (SUDs) in response to monetary reward tasks. Taken together, these findings signal an emerging research frontier to establish RewP as a clinical biomarker and create a compelling mandate for causal investigation. Low-frequency neural oscillations are the key mechanisms facilitating long-distance prefrontal connectivity and interregional communication. Delta oscillations (2.5Hz) in medial and left lateral prefrontal cortexes are closely linked to RewP and reward prediction error signaling, while theta oscillations (6Hz) index cognitive control and prefrontal regulatory engagement during reward processing. Disruptions in both bands have been well documented in MDD, to a more limited extent, in cannabis-using populations. The proposed experiment will causally test whether sham, delta, and theta frequency tACS can alter motivation and reward responsivity (behaviourally [Effort behaviour] and neurally [RewP, delta power]), in participants with disorder of reward dysfunction, CUD, MDD, and healthy controls. Findings from the proposed study will aid in mechanistic understanding of prefrontal circuits underlying reward impairment in CUD and MDD, and ultimately enable for the development of novel brain stimulation techniques to target disorder-maintaining anhedonia. The investigators hypothesise that delta tACS will modulate reward responsivity in participants with disorders of reward. Such that, during the EEfRT Task delta stimulation will enhance reward responsive goal directed behaviour (Behavioral H1) and delta phase connectivity between left lateral and medial frontal electrodes (Neural H1) at effort decision period. As well as greater reward positivity (RewP; Neural 2), and win vs. loss delta power and phase coherence at feedback (Neural H3).
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Zoe Howell Doctoral Student PI, M.Res.
- Número de teléfono: 850-644-2445
- Correo electrónico: brains@psy.fsu.edu
Ubicaciones de estudio
-
-
Florida
-
Tallahassee, Florida, Estados Unidos, 32306-4301
- Aún no reclutando
- The BRAINS Lab at Florida State University
-
Contacto:
- Zoe A Doctoral Student PI, M.Res.
- Número de teléfono: 850-644-2445
- Correo electrónico: brains@psy.fsu.edu
-
Tallahassee, Florida, Estados Unidos, 32306-4301
- Reclutamiento
- The Riddle Lab at Florida State University
-
Contacto:
- Zoe S Post baccalaureate Researcher, B.A.
- Número de teléfono: (850) 644-9869
- Correo electrónico: RiddleLabFSU@gmail.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria (General):
- Aged between 18 - 55 years old.
- Able to provide informed consent
- Have normal to corrected vision
- Willing to comply with all study procedures and be available for the duration of the study
- Speak and understand English.
- Negative THC saliva test and alcohol breathalyzer at all lab visits.
- Negative UTOX for any substance other than THC.
Exclusion Criteria (General):
- Mania history (Bipolar I, or current mania).
- Psychosis history.
- Current suicide intent (score >4 on C-SRSS, or intent >0 on SRA)
- Current moderate-to-severe SUD or AUD (Except CUD and nicotine for NEMO-CUD).
- Current pregnancy.
- Seizure, neurological conditions, or brain surgery history.
- Implanted medical devices (e.g., cochlear implants, cardiac pacemakers).
- Change in psychotropic medication in the past 3 months (i.e., medication needs to be stable for 12 weeks).
- Use of seizure threshold lowering medication (e.g., Stimulants, Benzos, SNRIs, Antipsychotics [Adderall, Vyvanse, Xanax, Wellbutrin, Cymbalta, Lithium] - SSRIs not exclusionary).
Specific CUD Inclusion:
- Avg. 6+ cannabis use days per week over the past 3-months, and 24+ cannabis use days in the past 30 days.
- Primary delta-9 or THC-A cannabis flower or vape concentrate user.
- Current moderate-to-severe CUD (4+ criteria in the past year, at least one criterion other than craving must be met in the past three months).
- Cannabis is the primary substance of use (Nicotine dependence is allowable)
- Not currently receiving treatment for cannabis, planning to immediately quit or reduce use.
- Lifetime history of MDE/PDD must have lifetime anhedonia symptom and/or heavy cannabis user (3+ sessions daily for at least past year including the past 3-months and past 30 days).
Specific MDD Inclusion:
- Current MDE diagnosis.
- No lifetime history of severe SUD.
- No current moderate-to-severe SUD.
- 100% of NEMO-MDD participants elevated anhedonia on TEPS-C (i.e., 32 or lower on TEPS-C subscale).
Specific Control Inclusion:
- No current or historical psychiatric diagnosis.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Delta tACS
All participants receive delta (2.5 Hz), theta (6 Hz), and sham tACS across three separate sessions, separated by a 7-10 day washout. Session order is randomised and counterbalanced using a balanced Latin square, within each diagnostic group (CUD, MDD, healthy control). Stimulation is interleaved between the 8 blocks of the EEfRT (e.g., block 1 with stimulation, block 2 without, etc.). EEG activity will be recorded throughout the non-stimulation 4 blocks and proceeding interleaved non-stimulation blocks. |
Approximately 20-minutes of delta stimulation (2.5Hz) applied to F3 (returns AF7, FC5, FC1) and AFz (returns Fp1, Fp2, F2). Transcranial Alternating Current Stimulation Device is NeuroConn DC-Stimulator MC. |
|
Comparador activo: Theta tACS
All participants receive delta (2.5 Hz), theta (6 Hz), and sham tACS across three separate sessions, separated by a 7-10 day washout. Session order is randomised and counterbalanced using a balanced Latin square, within each diagnostic group (CUD, MDD, healthy control). Stimulation is interleaved between the 8 blocks of the EEfRT (e.g., block 1 with stimulation, block 2 without, etc.). EEG activity will be recorded throughout the non-stimulation 4 blocks and proceeding interleaved non-stimulation blocks. |
Approximately 20-minutes of theta stimulation (6Hz) applied to F3 (returns AF7, FC5, FC1) and AFz (returns Fp1, Fp2, F2). Transcranial Alternating Current Stimulation Device is NeuroConn DC-Stimulator MC. |
|
Comparador falso: Sham tACS
All participants receive delta (2.5 Hz), theta (6 Hz), and sham tACS across three separate sessions, separated by a 7-10 day washout. Session order is randomised and counterbalanced using a balanced Latin square, within each diagnostic group (CUD, MDD, healthy control). Stimulation is interleaved between the 8 blocks of the EEfRT (e.g., block 1 with stimulation, block 2 without, etc.). EEG activity will be recorded throughout the non-stimulation 4 blocks and proceeding interleaved non-stimulation blocks. |
The tACS stimulation is briefly turned on and off over the course of 15-30 seconds. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Effort-updating behavior during decision period.
Periodo de tiempo: Baseline (Day 0), Sham Session (Day 1-10, or Day 10-20, or Day 20-30), Theta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30), Delta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30). Specific range depends on particular counterbalanced order.
|
The % of hard effort choices selected following a win versus following a loss. |
Baseline (Day 0), Sham Session (Day 1-10, or Day 10-20, or Day 20-30), Theta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30), Delta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30). Specific range depends on particular counterbalanced order.
|
|
Delta phase coherence between left lateral and medial frontal electrodes during decision period following a win versus following a loss.
Periodo de tiempo: Baseline (Day 0), Sham Session (Day 1-10, or Day 10-20, or Day 20-30), Theta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30), Delta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30). Specific range depends on particular counterbalanced order.
|
Electrical activity of the brain will be recorded via EEG during performance of the task and neurostimulation. Delta phase connectivity between left lateral and medial frontal electrodes during the decision period following a win versus following a loss. |
Baseline (Day 0), Sham Session (Day 1-10, or Day 10-20, or Day 20-30), Theta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30), Delta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30). Specific range depends on particular counterbalanced order.
|
|
Reward positivity amplitude
Periodo de tiempo: Baseline (Day 0), Sham Session (Day 1-10, or Day 10-20, or Day 20-30), Theta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30), Delta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30). Specific range depends on particular counterbalanced order.
|
Electrical activity of the brain will be recorded via EEG during performance of the task and neurostimulation. Reward positivity amplitude to wins vs. losses. |
Baseline (Day 0), Sham Session (Day 1-10, or Day 10-20, or Day 20-30), Theta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30), Delta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30). Specific range depends on particular counterbalanced order.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Delta event-related spectral power
Periodo de tiempo: Baseline (Day 0), Sham Session (Day 1-10, or Day 10-20, or Day 20-30), Theta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30), Delta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30). Specific range depends on particular counterbalanced order.
|
Electrical activity of the brain will be recorded via EEG during performance of the task and neurostimulation. Delta power to wins vs. losses. |
Baseline (Day 0), Sham Session (Day 1-10, or Day 10-20, or Day 20-30), Theta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30), Delta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30). Specific range depends on particular counterbalanced order.
|
|
Delta intertrial phase coherence
Periodo de tiempo: Baseline (Day 0), Sham Session (Day 1-10, or Day 10-20, or Day 20-30), Theta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30), Delta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30). Specific range depends on particular counterbalanced order.
|
Electrical activity of the brain will be recorded via EEG during performance of the task and neurostimulation. Delta intertrial phase coherence to wins vs. losses. |
Baseline (Day 0), Sham Session (Day 1-10, or Day 10-20, or Day 20-30), Theta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30), Delta Stim. Session (Day 1-10, or Day 10-20, or Day 20-30). Specific range depends on particular counterbalanced order.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Richard J Macatee, Ph.D., Florida State University
Publicaciones y enlaces útiles
Publicaciones Generales
- Byrd KJ, Johnston BW, Culp S, Kreutzer KA, Way BM, Phan KL, Gorka SM. Neural reward sensitivity and longitudinal patterns of alcohol and cannabis use in college-aged youth. Drug Alcohol Depend. 2026 Apr 1;281:113079. doi: 10.1016/j.drugalcdep.2026.113079. Epub 2026 Feb 10.
- Proudfit GH. The reward positivity: from basic research on reward to a biomarker for depression. Psychophysiology. 2015 Apr;52(4):449-59. doi: 10.1111/psyp.12370. Epub 2014 Oct 17.
- Murray CH, Glazer JE, Lee R, Nusslock R, de Wit H. Delta9-THC reduces reward-related brain activity in healthy adults. Psychopharmacology (Berl). 2022 Sep;239(9):2829-2840. doi: 10.1007/s00213-022-06164-y. Epub 2022 May 25.
- Joyner KJ, Bowyer CB, Yancey JR, Venables NC, Foell J, Worthy DA, Hajcak G, Bartholow BD, Patrick CJ. Blunted Reward Sensitivity and Trait Disinhibition Interact to Predict Substance Use Problems. Clin Psychol Sci. 2019;7(5):1109-1124. doi: 10.1177/2167702619838480. Epub 2019 Sep 1.
- Riddle J, Alexander ML, Schiller CE, Rubinow DR, Frohlich F. Reward-Based Decision-Making Engages Distinct Modes of Cross-Frequency Coupling. Cereb Cortex. 2022 May 14;32(10):2079-2094. doi: 10.1093/cercor/bhab336.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Manifestaciones neurológicas
- Enfermedades del Sistema Nervioso
- Desordenes mentales
- Síntomas de comportamiento
- Manifestaciones neuroconductuales
- Trastornos del estado de ánimo
- Desorden depresivo
- Condiciones Patológicas, Signos y Síntomas
- Comportamiento
- Signos y síntomas
- Depresión
- Trastorno Depresivo Mayor
- Anhedonia
Otros números de identificación del estudio
- STUDY00007710
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
The IPD will only be shared under reasonable request. The investigators might not share IPD in order to keep participant confidentiality paramount.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .